Literature DB >> 32556220

Comments on: "Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity".

Olaf van Tellingen1, Mark C de Gooijer1, Jann N Sarkaria2, William F Elmquist3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32556220      PMCID： PMC7523448          DOI： 10.1093/neuonc/noaa112

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

1.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Authors:  Jeffrey R Infante; Leslie A Fecher; Gerald S Falchook; Sujatha Nallapareddy; Michael S Gordon; Carlos Becerra; Douglas J DeMarini; Donna S Cox; Yanmei Xu; Shannon R Morris; Vijay G R Peddareddigari; Ngocdiep T Le; Lowell Hart; Johanna C Bendell; Gail Eckhardt; Razelle Kurzrock; Keith Flaherty; Howard A Burris; Wells A Messersmith
Journal:  Lancet Oncol       Date:  2012-07-16       Impact factor: 41.316

2.  Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity.

Authors:  Antje Arnold; Ming Yuan; Antionette Price; Lauren Harris; Charles G Eberhart; Eric H Raabe
Journal:  Neuro Oncol       Date:  2020-04-15       Impact factor: 12.300

Review 3.  Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.

Authors:  O van Tellingen; B Yetkin-Arik; M C de Gooijer; P Wesseling; T Wurdinger; H E de Vries
Journal:  Drug Resist Updat       Date:  2015-03-06       Impact factor: 18.500

4.  Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.

Authors:  Shruthi Vaidhyanathan; Rajendar K Mittapalli; Jann N Sarkaria; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2014-05-29       Impact factor: 3.922

Review 5.  Pediatric low-grade gliomas: next biologically driven steps.

Authors:  David T W Jones; Mark W Kieran; Eric Bouffet; Sanda Alexandrescu; Pratiti Bandopadhayay; Miriam Bornhorst; David Ellison; Jason Fangusaro; Michael J Fisher; Nicholas Foreman; Maryam Fouladi; Darren Hargrave; Cynthia Hawkins; Nada Jabado; Maura Massimino; Sabine Mueller; Giorgio Perilongo; Antoinette Y N Schouten van Meeteren; Uri Tabori; Katherine Warren; Angela J Waanders; David Walker; William Weiss; Olaf Witt; Karen Wright; Yuan Zhu; Daniel C Bowers; Stefan M Pfister; Roger J Packer
Journal:  Neuro Oncol       Date:  2018-01-22       Impact factor: 12.300

Review 6.  Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

Authors:  Jann N Sarkaria; Leland S Hu; Ian F Parney; Deanna H Pafundi; Debra H Brinkmann; Nadia N Laack; Caterina Giannini; Terence C Burns; Sani H Kizilbash; Janice K Laramy; Kristin R Swanson; Timothy J Kaufmann; Paul D Brown; Nathalie Y R Agar; Evanthia Galanis; Jan C Buckner; William F Elmquist
Journal:  Neuro Oncol       Date:  2018-01-22       Impact factor: 12.300
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.